print
gohome
Print Edition
XTL Biopharmaceuticals names CEO
Yigal Grayeff
01/04/2006
Rehovot-based XTL Biopharmaceuticals named Ron Bentsur as chief executive, ending an 11-month period without a CEO.
Rehovot-based XTL Biopharmaceuticals named Ron Bentsur as chief executive, ending an 11-month period without a CEO. In February, rebel investors persuaded shareholders to oust interim chairman and chief executive Elkan Gamzu and two other directors. XTL appointed Michael Weiss as interim chairman in March and then non-executive chairman in August, but failed to appoint a CEO until now. XTL said on Tuesday that Bentsur comes from US company Keryx Biopharmaceuticals, where he is vice president for finance and investor relations, a job he will continue to carry out for a transitional period.
print gohome
JPost.com: Arab-Israeli Conflict | Israel News | Diaspora | Middle East | Opinion | Premium | Blogs | Not Just News | Edition Francaise | Green Israel

Copyright © 2014 Jpost Inc. All rights reserved • Terms of UsePrivacy Policy